Literature DB >> 24218310

Value of EUS in early detection of pancreatic ductal adenocarcinomas in patients with intraductal papillary mucinous neoplasms.

Ken Kamata1, Masayuki Kitano1, Masatoshi Kudo1, Hiroki Sakamoto1, Kumpei Kadosaka1, Takeshi Miyata1, Hajime Imai1, Kiyoshi Maekawa2, Takaaki Chikugo3, Masashi Kumano4, Tomoko Hyodo4, Takamichi Murakami4, Yasutaka Chiba5, Yoshifumi Takeyama6.   

Abstract

BACKGROUND AND STUDY AIMS: Pancreatic ductal adenocarcinomas (PDAC) sometimes arise in patients with intraductal papillary mucinous neoplasms (IPMNs). This study examined the incidence of PDACs concomitant to or derived from branch duct IPMNs. The usefulness of endoscopic ultrasonography (EUS) relative to other imaging methods for detecting these tumors was also assessed. PATIENTS AND METHODS: This retrospective study used data from clinical records and imaging studies that were collected prospectively. During 2001-2009, 167 consecutive patients with IPMNs underwent EUS, ultrasonography, computed tomography (CT), and magnetic resonance imaging (MRI). The 102 patients whose branch duct IPMNs lacked mural nodules/symptoms and thus did not qualify for resection were followed up by semiannual EUS and annual ultrasonography, CT, and MRI. The sensitivity and specificity with which the four modalities detected IPMN-derived and -concomitant PDACs at the first examination and throughout the study period were evaluated. The rate of PDAC development during follow-up was analyzed by the Kaplan-Meier method.
RESULTS: A total of 17 IPMN-derived and 11 IPMN-concomitant PDACs were diagnosed at the first examination. Lesions that did not qualify for resection or chemotherapy were followed up for a median of 42 months. Seven IPMN-concomitant PDACs and no IPMN-derived PDACs were detected during follow-up. The 3- and 5-year rates of IPMN-concomitant PDAC development were 4.0% and 8.8%, respectively. At the first examination, EUS was superior to other imaging modalities in terms of IPMN-derived and -concomitant PDAC detection. Throughout the study period, including follow-up, EUS was significantly better at detecting IPMN-concomitant PDACs than the other modalities.
CONCLUSIONS: IPMN-concomitant PDACs are quite often found at diagnosis and during follow-up. EUS examination of the whole pancreas plays an important role in the management of IPMNs as it allows the early detection of these small invasive carcinomas. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2013        PMID: 24218310     DOI: 10.1055/s-0033-1353603

Source DB:  PubMed          Journal:  Endoscopy        ISSN: 0013-726X            Impact factor:   10.093


  36 in total

Review 1.  Diagnosis and management of cystic lesions of the pancreas.

Authors:  William R Brugge
Journal:  J Gastrointest Oncol       Date:  2015-08

2.  Differential diagnosis of benign and malignant branch duct intraductal papillary mucinous neoplasm using contrast-enhanced endoscopic ultrasonography.

Authors:  Hirofumi Harima; Seiji Kaino; Shuhei Shinoda; Michitaka Kawano; Shigeyuki Suenaga; Isao Sakaida
Journal:  World J Gastroenterol       Date:  2015-05-28       Impact factor: 5.742

Review 3.  Current best practice and controversies in the follow up of patients with asymptomatic branch duct IPMN of the pancreas.

Authors:  Masao Tanaka
Journal:  HPB (Oxford)       Date:  2016-07-21       Impact factor: 3.647

4.  Risk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long-term Surveillance.

Authors:  Marcia Irene Canto; Jose Alejandro Almario; Richard D Schulick; Charles J Yeo; Alison Klein; Amanda Blackford; Eun Ji Shin; Abanti Sanyal; Gayane Yenokyan; Anne Marie Lennon; Ihab R Kamel; Elliot K Fishman; Christopher Wolfgang; Matthew Weiss; Ralph H Hruban; Michael Goggins
Journal:  Gastroenterology       Date:  2018-05-24       Impact factor: 22.682

Review 5.  International consensus on the management of intraductal papillary mucinous neoplasm of the pancreas.

Authors:  Masao Tanaka
Journal:  Ann Transl Med       Date:  2015-11

6.  Pancreatic Resection for Side-Branch Intraductal Papillary Mucinous Neoplasm (SB-IPMN): a Contemporary Single-Institution Experience.

Authors:  John D Dortch; John A Stauffer; Horacio J Asbun
Journal:  J Gastrointest Surg       Date:  2015-06-09       Impact factor: 3.452

7.  Current recommendations for surveillance and surgery of intraductal papillary mucinous neoplasms may overlook some patients with cancer.

Authors:  Andrew H Nguyen; Paul A Toste; James J Farrell; Barbara M Clerkin; Jennifer Williams; V Raman Muthusamy; Rabindra R Watson; James S Tomlinson; O Joe Hines; Howard A Reber; Timothy R Donahue
Journal:  J Gastrointest Surg       Date:  2014-11-06       Impact factor: 3.452

Review 8.  Screening for Pancreatic Cancer.

Authors:  Saowanee Ngamruengphong; Marcia Irene Canto
Journal:  Surg Clin North Am       Date:  2016-12       Impact factor: 2.741

9.  Role of pancreatic juice cytology in the preoperative management of intraductal papillary mucinous neoplasm of the pancreas in the era of international consensus guidelines 2012.

Authors:  Takao Ohtsuka; Taketo Matsunaga; Hideyo Kimura; Yusuke Watanabe; Koji Tamura; Noboru Ideno; Teppei Aso; Yoshihiro Miyasaka; Junji Ueda; Shunichi Takahata; Takashi Osoegawa; Hisato Igarashi; Tetsuhide Ito; Yasuhiro Ushijima; Fumihiko Ookubo; Yoshinao Oda; Kazuhiro Mizumoto; Masao Tanaka
Journal:  World J Surg       Date:  2014-11       Impact factor: 3.352

Review 10.  Endoscopic ultrasonography for surveillance of individuals at high risk for pancreatic cancer.

Authors:  Gabriele Lami; Maria Rosa Biagini; Andrea Galli
Journal:  World J Gastrointest Endosc       Date:  2014-07-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.